Edwards announces six-month data from transcatheter tricuspid replacement program

Irvine, calif., nov. 6, 2021 /prnewswire/ -- edwards lifesciences corporation (nyse: ew) announced that results from a clinical trial of the company's evoque transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months.
EW Ratings Summary
EW Quant Ranking